company background image
532637 logo

Mangalam Drugs & Organics BSE:532637 Stock Report

Last Price

₹98.49

Market Cap

₹1.6b

7D

-5.1%

1Y

-13.1%

Updated

15 Apr, 2024

Data

Company Financials

Mangalam Drugs & Organics Limited

BSE:532637 Stock Report

Market Cap: ₹1.6b

532637 Stock Overview

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.

532637 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Mangalam Drugs & Organics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mangalam Drugs & Organics
Historical stock prices
Current Share Price₹98.49
52 Week High₹132.40
52 Week Low₹85.16
Beta0.73
1 Month Change-2.10%
3 Month Change-4.47%
1 Year Change-13.14%
3 Year Change-7.65%
5 Year Change83.07%
Change since IPO206.82%

Recent News & Updates

Recent updates

Shareholder Returns

532637IN PharmaceuticalsIN Market
7D-5.1%-3.0%-1.7%
1Y-13.1%56.8%45.0%

Return vs Industry: 532637 underperformed the Indian Pharmaceuticals industry which returned 57.5% over the past year.

Return vs Market: 532637 underperformed the Indian Market which returned 46.9% over the past year.

Price Volatility

Is 532637's price volatile compared to industry and market?
532637 volatility
532637 Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.8%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 532637's share price has been volatile over the past 3 months.

Volatility Over Time: 532637's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1972523Govardhan Dhootwww.mangalamdrugs.com

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base.

Mangalam Drugs & Organics Limited Fundamentals Summary

How do Mangalam Drugs & Organics's earnings and revenue compare to its market cap?
532637 fundamental statistics
Market cap₹1.56b
Earnings (TTM)-₹169.87m
Revenue (TTM)₹3.59b

0.4x

P/S Ratio

-9.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
532637 income statement (TTM)
Revenue₹3.59b
Cost of Revenue₹2.41b
Gross Profit₹1.19b
Other Expenses₹1.36b
Earnings-₹169.87m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 30, 2024

Earnings per share (EPS)-10.73
Gross Margin33.09%
Net Profit Margin-4.73%
Debt/Equity Ratio71.4%

How did 532637 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.